Decanoic acid reduces extracellular prostaglandin accumulation, inhibits MRP4 transport, and enhances low-dose dexamethasone effects in IL-1β-stimulated human osteoarthritis synoviocytes
- 1Trauma Research, Swedish Medical Center , , ,
Abstract
Objective: Persistent extracellular prostaglandin signaling contributes to synovial inflammation and pain in osteoarthritis (OA), although prostaglandin E2 (PGE2) can also have context-dependent homeostatic functions. Decanoic acid (DA) is a 10-carbon medium-chain fatty acid with reported peroxisome proliferator-activated receptor-modulating and anti-inflammatory activity. Its amphipathic carboxylate structure also made it an exploratory candidate for interaction with the hydrophobic organic-anion binding region of multidrug resistance protein 4 (MRP4/ABCC4). We tested whether DA changes prostaglandin compartmentalization and enhances the effect of very-low-dose dexamethasone (Dex) in interleukin-1β (IL-1β)-stimulated human OA fibroblast-like synoviocytes.
Methods: Primary human osteoarthritis fibroblast-like synoviocytes were stimulated with IL-1β and treated with DA, Dex, or their combination. Extracellular and intracellular prostaglandins were quantified by competitive ELISA. MRP4 inhibition was evaluated in inside-out HEK293 membrane vesicles overexpressing human MRP4 using ATP-dependent DHEAS transport, with MK-571 as the positive inhibitor control. Molecular docking and UHPLC-MS lipidomics were also performed. Replicates were independently cultured wells or pellets from the same donor
Results: DA reduced extracellular PGE2 and increased intracellular PGE2. With a fixed 0.1 nM Dex background, the fitted DA IC50 changed from 19.42 μM (95% CI, 11.14–32.49 μM) to 8.62 μM (95% CI, 4.69–15.26 μM) with an F-test P = 0.0402, indicating Das ability to potentiate the inhibitory effect of sub-nanomolar DEX. DA also reduced extracellular PGD2 and PGI2. In vesicles, DA inhibited MRP4-mediated DHEAS transport in a concentration-dependent manner (calculated IC50, approximately 33.86 μM), but PGE2 transport was not measured directly. Docking placed DA near the MK-571 reference pose. DA was also associated with increased 17(S)-HDHA and maresin 2 (MaR2).
Conclusions: In this single-donor proof-of-concept model, DA altered prostaglandin distribution, inhibited MRP4 probe-substrate transport, and enhanced extracellular prostaglandin suppression in the presence of low-dose Dex. The findings are consistent with, but do not prove, an MRP4-associated contribution to prostaglandin export. The increases in 17(S)-HDHA and MaR2 are associative and do not establish that intracellular PGE2 retention caused resolution signaling. Multi-donor validation, direct PGE2 transport studies, genetic MRP4 experiments, and intra-articular pharmacokinetic and safety studies are required.
Related
- Recorded Adverse Events and Patient-Reported Outcomes After Intra-articular Extracellular-Vesicle Product Administration for Knee Osteoarthritis: A Retrospective Single-Practice Case Series
- Multimodal hydrogel modulation of extracellular vesicle cargo to arrest post-traumatic osteoarthritis in murine models
- Extracellular Vesicles from Buccal Fat Pad-Derived Dedifferentiated Fat Cells Modulate Inflammatory Macrophage Responses and Attenuate Temporomandibular Joint Osteoarthritis
- The Soluble Secretome and Extracellular Vesicles of Synovial Fluid Cells Closely Resemble Synovial Membrane Fibroblasts over Articular Chondrocytes in Donor-Matched Isolates from Osteoarthritis Patients
- Extracellular Matrix Remodeling and Glycoprotein Biomarkers Across Osteoarthritis, Rheumatoid Arthritis, and Temporomandibular Disorders: A Systematic Review and Integrative Analysis
BibTeX
@article{williams2026decanoic,
title = {{Decanoic acid reduces extracellular prostaglandin accumulation, inhibits MRP4 transport, and enhances low-dose dexamethasone effects in IL-1β-stimulated human osteoarthritis synoviocytes}},
author = {Jason Williams and Melissa A. Hausburg and Gregory W. Thomas and Raphael Bar-Or and Kaysie Banton and David Bar-Or},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1876378},
url = {https://europepmc.org/article/PMC/PMC13727426},
note = {CC BY},
}
RIS
TY - JOUR
TI - Decanoic acid reduces extracellular prostaglandin accumulation, inhibits MRP4 transport, and enhances low-dose dexamethasone effects in IL-1β-stimulated human osteoarthritis synoviocytes
AU - Jason Williams
AU - Melissa A. Hausburg
AU - Gregory W. Thomas
AU - Raphael Bar-Or
AU - Kaysie Banton
AU - David Bar-Or
PY - 2026
DA - 2026/10/20
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1876378
UR - https://europepmc.org/article/PMC/PMC13727426
AB - Objective: Persistent extracellular prostaglandin signaling contributes to synovial inflammation and pain in osteoarthritis (OA), although prostaglandin E2 (PGE2) can also have context-dependent homeostatic functions. Decanoic acid (DA) is a 10-carbon medium-chain fatty acid with reported peroxisome proliferator-activated receptor-modulating and anti-inflammatory activity. Its amphipathic carboxylate structure also made it an exploratory candidate for interaction with the hydrophobic organic-anion binding region of multidrug resistance protein 4 (MRP4/ABCC4). We tested whether DA changes prostaglandin compartmentalization and enhances the effect of very-low-dose dexamethasone (Dex) in interleukin-1β (IL-1β)-stimulated human OA fibroblast-like synoviocytes. Methods: Primary human osteoarthritis fibroblast-like synoviocytes were stimulated with IL-1β and treated with DA, Dex, or their combination. Extracellular and intracellular prostaglandins were quantified by competitive ELISA. MRP4 inhibition was evaluated in inside-out HEK293 membrane vesicles overexpressing human MRP4 using ATP-dependent DHEAS transport, with MK-571 as the positive inhibitor control. Molecular docking and UHPLC-MS lipidomics were also performed. Replicates were independently cultured wells or pellets from the same donor Results: DA reduced extracellular PGE2 and increased intracellular PGE2. With a fixed 0.1 nM Dex background, the fitted DA IC50 changed from 19.42 μM (95% CI, 11.14–32.49 μM) to 8.62 μM (95% CI, 4.69–15.26 μM) with an F-test P = 0.0402, indicating Das ability to potentiate the inhibitory effect of sub-nanomolar DEX. DA also reduced extracellular PGD2 and PGI2. In vesicles, DA inhibited MRP4-mediated DHEAS transport in a concentration-dependent manner (calculated IC50, approximately 33.86 μM), but PGE2 transport was not measured directly. Docking placed DA near the MK-571 reference pose. DA was also associated with increased 17(S)-HDHA and maresin 2 (MaR2). Conclusions: In this single-donor proof-of-concept model, DA altered prostaglandin distribution, inhibited MRP4 probe-substrate transport, and enhanced extracellular prostaglandin suppression in the presence of low-dose Dex. The findings are consistent with, but do not prove, an MRP4-associated contribution to prostaglandin export. The increases in 17(S)-HDHA and MaR2 are associative and do not establish that intracellular PGE2 retention caused resolution signaling. Multi-donor validation, direct PGE2 transport studies, genetic MRP4 experiments, and intra-articular pharmacokinetic and safety studies are required.
SN - 2296-858X
ER -